Intermittent use of griseofulvin in tinea capitis.
A total of 247 patients with tinea capitis were divided into two groups and treated with griseofulvin in two different ways: the first group received the drug every other day, and the second received it twice a week. The dosage was 5 mg/lb, with a maximum of 1 gm/day in both cases. In the first group, 99 percent of the patients were completely cured within seven weeks. Of those who received the griseofulvin twice a week, 91 percent were completely cleared within eight weeks. None of those in either group showed any signs of side effects from the medication.
D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006118:Griseofulvin / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007492:Iran; D008297:Male; D014006:Tinea Capitis / Q000150:complications / Q000188:drug therapy*; D014007:Tinea Favosa / Q000150:complications
D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D006118:Griseofulvin